anle 138bAlternative Names: anle138b
Latest Information Update: 28 Jul 2016
At a glance
- Originator Ludwig-Maximilians-University; Max Planck Institute for Biophysical Chemistry
- Developer Modag
- Mechanism of Action Protein aggregation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Creutzfeldt-Jakob disease; Parkinson's disease